

1 Longitudinal Electrocochleography as an Objective Measure of Serial Behavioral Audiometry in Electro-

2 Acoustic Stimulation Patients

3 Viral D. Tejani, AuD, PhD^{1 2 3 4}

4 Jeong-Seo Kim, AuD, PhD^{3 4 5}

5 Christine P. Etler, AuD³

6 Jeffrey Skidmore, PhD⁶

7 Yi Yuan, PhD⁶

8 Shuman He, MD, PhD⁶

9 Marlan R. Hansen, MD^{3 7 8}

10 Bruce J. Gantz, MD^{3 7}

11 Paul J. Abbas, PhD^{3 4}

12 Carolyn J. Brown, PhD^{3 4}

13

14 1. Department of Otolaryngology-Head and Neck Surgery, University Hospitals Cleveland Medical
15 Center, Cleveland, OH

16 2. Department of Otolaryngology-Head and Neck Surgery, Case Western Reserve University School of
17 Medicine, Cleveland, OH

18 3. Department of Otolaryngology-Head and Neck Surgery, University of Iowa Hospitals and Clinics,
19 Iowa City, IA

20 4. Department of Communication Sciences and Disorders, University of Iowa, Iowa City, IA

21 5. Hearing Research Laboratory, Samsung Medical Center, Seoul, South Korea

22 6. Department of Otolaryngology-Head and Neck Surgery, Eye and Ear Institute, The Ohio State
23 University Wexner Medical Center, Columbus, OH

24 7. Department of Neurosurgery, University of Iowa Hospitals and Clinics, Iowa City, IA

25 8. Department of Molecular Physiology and Biophysics, University of Iowa Hospitals and Clinics, Iowa
26 City, IA

27

28 Email Address for Correspondence:

29 Viral Tejani, AuD, PhD

30 Viral.Tejani@UHhospitals.org

31

32 **ORCID IDs:** Viral Tejani 0000-0001-7585-9619

33 Bruce Gantz 0000-0002-9916-6048

34 Marlan Hansen 0000-0002-6884-4897

35 Jeffrey Skidmore 0000-0002-6015-7574

36 **Funding:** National Institute on Deafness and Other Communicative Disorders (P50 DC 000242, PI:

37 Gantz; 1R01 DC017846, PI: He; R21 DC019458, PI: He)

38 National Institute of General Medical Sciences (1R01 DC016038, PI: He)

39 **Conflict of Interest:** BJG is a consultant for Cochlear Ltd.
40 MRH is co-founder and Chief Medical Officer for iotaMotion, Inc.
41 VDT is a consultant for iotaMotion, Inc.
42 All other authors declare that they have no conflict of interest.

43 **Word Counts:**

44 **Key Words:** Electrocochleography, Hybrid, Electric-Acoustic Simulation, Hearing
45 Preservation
46

PAPER IN REVIEW

47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68

ABSTRACT (250 word limit)

Minimally traumatic surgical techniques and advances in cochlear implant (CI) electrode array designs have allowed acoustic hearing present in a CI candidate prior to surgery to be preserved post-operatively. As a result, these patients benefit from combined electric-acoustic stimulation (EAS) post-operatively. However, 30-40% of EAS CI users experience a partial loss of hearing up to 30 dB after surgery. In the present study, electrocochleography (ECoG) was used to study cochlear microphonic (hair cell response) and auditory nerve neurophonic (neural response) in patients with preserved hearing and patients with loss of hearing. These measures were obtained longitudinally over the course of CI use. At each test session, ECoG amplitude growth functions for several low-frequency stimuli were obtained. The threshold, slope, and suprathreshold amplitude at a fixed stimulation level was obtained from each growth function at each time point. Subjects were categorized as having stable hearing or loss of hearing. Longitudinal linear mixed effects models were used study trends in ECoG thresholds, slopes, and amplitudes for these two categories of subjects. Results showed that CM and ANN thresholds and amplitudes were stable in CI users with preserved residual hearing. CM and ANN thresholds increased (worsened) while CM and ANN amplitudes decreased (worsened) for those with delayed hearing loss. The slope did not distinguish between subjects with stable hearing and subjects with delayed loss of hearing. These results provide a new application of post-operative ECoG as an objective tool to monitor residual hearing and understand the pathophysiology of delayed hearing loss.

69

INTRODUCTION

70

71 Surgical techniques and cochlear implant (CI) electrode array designs have evolved in the last two
72 decades to the extent that acoustic hearing present in a CI candidate prior to surgery can be preserved
73 post-operatively. As a result, these patients benefit from combined electric-acoustic stimulation (EAS)
74 post-operatively, where the electrode array provides electrical stimulation of the auditory nerve and an
75 integrated hearing aid provides acoustic amplification. Since the proof of concept was demonstrated in
76 the late 1990s (von Ilberg et al 1997; Gantz & Turner 2003), studies in the last two decades have
77 consistently shown the benefits of EAS over conventional electrical-only stimulation for speech
78 understanding in noise (Turner et al, 2004; Tejani & Brown 2020), perception of spectral and temporal
79 cues (Gifford et al. 2008, 2010; Golub et al 2012; Tejani & Brown, 2020), music appreciation (Gfeller et
80 al. 2006; Brockmeier et al. 2010), and localization (Dunn et al, 2010).

81

82 The benefits of EAS are maximized if residual acoustic hearing is successfully preserved long-term. It is
83 critical for audiologists to conduct behavioral pure-tone audiometric testing longitudinally to monitor
84 hearing thresholds and program the hearing aid portion of the EAS sound processors appropriately.
85 Cochlear Nucleus L24 Hybrid CI user can generally maintain stable low-frequency audiometric thresholds
86 (125, 250, and 500 Hz) of 50 - 70 dB HL up to five years post-surgery (Gantz et al, 2018; Roland et al,
87 2018) which is within the capabilities of the integrated hearing aid to provide amplification. However,
88 about 30-40% of EAS CI users experience a partial loss up to 30 dB immediately and/or several months
89 after surgery. In most cases, this additional hearing loss is not severe enough to preclude use of acoustic
90 amplification (Lenarz et al. 2013; Van Abel et al. 2015; Scheperle et al. 2017; Pillsbury et al. 2018; Roland
91 et al. 2018), but the loss of hearing can have a negative effect on performance and is an outcome that
92 clinicians and researchers attempt to minimize.

93
94 Several theories are present as to why EAS CI users lose hearing post-operatively. Hearing loss
95 immediately after surgery may result from insertion / structural trauma (Adunka et al, 2010). Delayed
96 hearing loss that occurs months after surgery could be due to intracochlear fibrosis / osteoneogenesis
97 (O’Leary et al. 2013; Quesnel et al. 2016; Foggia et al, 2019; Tejani et al, 2022) which could affect
98 cochlear mechanics (Choi & Oghalai 2005). Histological data have also suggested compromised
99 endocochlear potentials (Tanaka et al. 2014; Reiss et al. 2015) while not implicating hair cell / neural
100 damage. Hair cell, neural, pre-synaptic ribbon counts, and post-synaptic receptor counts are stable post-
101 loss of acoustic hearing (O’Leary et al. 2013; Tanaka et al. 2014; Reiss et al. 2015; Quesnel et al. 2016;
102 but see Li et al. 2020 who reported cochlear neuropathy/synaptopathy).

103
104 To address some of these theories, our institution has used electrocochleography (ECoG) as an objective
105 electrophysiological tool to assess peripheral auditory function in EAS CI users (Abbas et al. 2017; Kim et
106 al. 2018; Tejani et al. 2019, 2021; see Eggermont 2017 for review on ECoG). The cochlear microphonic
107 (CM) portion of the electrocochleogram reflects hair cell function, while the auditory nerve neurophonic
108 (ANN) represents sustained phase-locked neural activity. Two other components of the
109 electrocochleogram are the summing potential (SP) and the compound action potential (CAP). The SP
110 presents as a baseline shift and may contain both hair cell and neural contributions (Pappa et al. 2019)
111 while the CAP is a neural response occurring at the stimulus onset and offset. The underlying rationale for
112 use of ECoG in EAS studies is that both hair cell and neural function can be assessed in response to
113 acoustic stimulation, thereby providing an objective measure of residual acoustic auditory function.
114 Thus, changes in hair cell potentials and/or neural potentials with loss of residual hearing could shed
115 light on hearing loss etiologies (e.g., Tejani et al, 2021).

116

117 Previous studies from our institution and others have validated ECoG as a potential tool to assess
118 residual hearing and cochlear function. CM and ANN thresholds correlate strongly with behavioral
119 audiometric thresholds (Abbas et al, 2017; Koka et al, 2017), which can aid with programming the
120 hearing aid portion of the EAS sound processor (Agrawal et al, 2021). Intraoperative measures of ECoG
121 are used to guide cochlear implantation to minimize cochlear trauma (Bester et al, 2022; Lenarz et al,
122 2022) and have been shown to correlate with post-operative speech understanding (Fontenot et al,
123 2019; Canfarotta et al, 2021; Walia et al, 2022). One important aspect of ECoG that hasn't been
124 sufficiently validated is the long-term stability of these measures. Our previous studies have mainly
125 focused on test-retest reliability of ECoG thresholds at two time points for EAS patients with stable
126 hearing and EAS patients with loss of hearing. These studies also presented limited longitudinal
127 suprathreshold ECoG amplitude data (Abbas et al, 2017; Kim et al 2018; Tejani et al, 2019). These data
128 did indeed show that ECoG measures are stable at two time points for EAS patients with stable hearing
129 while changes in ECoG did mirror changes in behavioral audiometry for EAS patients with fluctuating
130 acoustic hearing or loss of acoustic hearing. However, if ECoG is to be used as an objective method of
131 monitoring residual hearing over the course of EAS CI use, then repeated measures of these potentials
132 should remain stable over time for EAS CI users with stable post-operative hearing preservation.
133 Additionally, changes in behavioral audiometry for EAS CI users with loss of residual hearing should also
134 be reflected in changes in ECoG measures.

136 METHODS

137
138 This study was approved by the University of Iowa Institutional Review Board (IRB 201805740). Subjects
139 signed an informed consent form.

140

141 **Subject Population and Classification**

142

143 A pool of 40 subjects implanted with Cochlear Corporation electrode arrays were included in this study.

144 They were all implanted between the years 2006 and 2021. All subjects were adults who presented with

145 significant residual acoustic hearing at time of implantation. The average pre-operative low-frequency

146 pure tone average (PTA) of 125 to 500 Hz was 40.88 ± 13.12 dB HL.

147

148 Subjects were seen at several time points post-operatively for both behavioral audiometry and ECoG

149 recordings. Time points included 0.5, 1, 3, 6, 12 months, and annually after 12 months, though not all

150 subjects were tested at all time points and there were subjects enrolled into the study years post-

151 surgery. While behavioral audiometry was done at initial activation, ECoG recordings were not done at

152 that time point. Changes in pure-tone audiometric thresholds relative to the baseline appointment were

153 used to classify subjects into two groups: one group of subjects with stable acoustic hearing and another

154 group of subjects with loss of acoustic hearing. The baseline appointment was the first appointment at

155 which both audiometry and ECoG recordings were done. For purposes of subject classification, loss of

156 acoustic hearing was defined as a > 5 dB decline in behavioral threshold between the subject's most

157 recent appointment and the baseline appointment. We focused on 250, 500, 750, and 1000 Hz

158 audiometry and, as explained in more details in a subsequent section, we conducted analyses for each

159 frequency separately. Thus, the number of subjects in the stable vs hearing loss group may differ for

160 each frequency.

161

162 Table 1 describes subject demographics in more detail, including array type, classification into stable vs

163 hearing loss group, the use of intraoperative ECoG monitoring, and electrode insertion depth. The last

164 two variables are explained in the next section.

165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188

--- TABLE 1 HERE ---

Cochlear Implantation

Various Cochlear Corporation electrode arrays were used in this study, including the S8 / S12 / L24 Hybrids arrays, CI 422/522/622 slim lateral wall arrays, and the CI 624 Slim 20. Table 2 describes the arrays in detail, including length, insertion depth, and number of electrodes.

Implantation was performed by authors BJG and MRH at the University of Iowa Hospitals and Clinics under hearing preservation protocols using soft insertion techniques. Subjects received intravenous dexamethasone during surgery, a 1-week course of prednisone (1 mg/kg/day) beginning immediately postoperatively, and a second 1-week course beginning the day prior to activation of the CI. The steroids were an attempt to reduce inflammatory responses and subsequent loss of hearing that may be associated with surgical trauma (e.g., Rauch et al. 2011). Subjects implanted prior to 2013 were implanted via a cochleostomy while later subjects were implanted via the round window in attempts to minimize cochlear trauma (e.g., Adunka et al. 2004). At the end of insertion, the electrode array was secured to the tegmen mastoideum to reduce chances of electrode migration and ensure stability of the intracochlear array. Cochlear implantation of recent patients was also done in conjunction with intraoperative ECoG measures to guide insertion trajectory and depth (Lenarz et al, 2021; Bester et al, 2022); in two cases partial electrode insertions were purposely performed to attempt to preserve residual acoustic hearing. Table 1 indicates which subjects were implanted in conjunction with intraoperative ECoG and which two subjects had partial insertions performed.

189 **Electrococheography Recordings**

190
191 Recordings were performed using a custom in-house system that utilizes Python programming and
192 version 2 of the Nucleus Implant Communicator (NIC) routines. These programs were used to trigger
193 acoustic stimulation and record a response from an intracochlear electrode (see Tejani et al, 2019 for
194 specific details on software and hardware adaptations). The stimuli were low-frequency tone bursts that
195 were presented to the implanted ear via an insert earphone. Presentation levels ranged from below
196 behavioral detection threshold to the maximal comfort level. A response was recorded from the most
197 apical electrode in the array. Stimuli were 24-ms tone bursts with a 1-cycle rise / fall time, or 1 ms,
198 whichever was longer, shaped by a cosine-squared window. Stimuli were presented at a 10-Hz
199 stimulation rate in both condensation and rarefaction polarities. Stimuli frequencies were 250, 500, 750,
200 and 1000 Hz.

201
202 Recordings were repeated at several time points after activation of the CI, typically coinciding with
203 clinical checkup appointments. Time points included 0.5, 1, 3, 6, 12 months, and annually after 12
204 months. Exact time points varied based on each subject's availability. Subjects were also seen for interim
205 appointments if they experienced a loss of acoustic hearing. Additionally, while recordings were
206 attempted for all stimulus frequencies, we focused on 500 Hz if there were time / subject availability
207 limitations.

208 209 **Statistical Analysis**

210
211 ECoG recordings were done at several levels from behavioral threshold level to the maximal comfort
212 levels. CM and ANN amplitudes were plotted as a function of stimulus level to construct amplitude

213 growth functions. As detailed in the “Electrococheography Amplitude Growth Functions” section of the
214 results section, three parameters were extracted – threshold, slope, and suprathreshold amplitude at a
215 fixed level. These parameters were extracted for all amplitude growth functions at all test frequencies
216 that were collected at every appointment. Changes in threshold, slope, and amplitude at each
217 appointment were calculated relative to baseline. These three metrics served as the dependent variable
218 as part of a linear mixed effects model (LME). The change in each dependent variable over time was
219 evaluated separately with LME models for two groups of subjects: subjects with stable hearing and
220 subjects with loss of hearing. For each LME model the deviation from baseline of the dependent
221 variable was the response variable, the fixed effect was time from baseline, and subject was the random
222 effect. No intercepts were included in the model to force the model to pass through the baseline
223 datapoint. In other words, only slope was considered for the fixed and random effects. Significance
224 values were adjusted using the False Discovery Rate to minimize potential Type I errors from repeated
225 analyses.

227 RESULTS

229 Electrococheography Amplitude Growth Functions

230
231 Responses to condensation and rarefaction stimuli were subtracted from one another to emphasize the
232 CM and added to one another to emphasize the ANN (Aran and Charlet de Sauvage 1976; Henry 1995;
233 Lichtenhan et al. 2013). Since this difference and summation technique does not result in a pure
234 separation of CM and ANN (Forgues et al. 2014; Abbas et al. 2017), we hereafter refer to the potentials
235 as CM/DIFF and ANN/SUM. A Fast Fourier Transform (FFT) analysis of the time domain data into the
236 frequency domain was then performed, resulting in a resolution of 37.74 Hz/bin.

237

238

--- FIGURE 1 ---

239

240 Figure 1 shows an example recording from one subject (622-5R) who was seen at his 12-month
241 appointment. The top left panel shows the resulting response to both condensation and rarefaction
242 polarities for a 500 Hz tone burst. The top middle and top right panels show the resulting CM/DIFF and
243 ANN/SUM recordings. The CM/DIFF waveform oscillates at a 500 Hz frequency while the ANN/SUM
244 waveform oscillates at a 1000 Hz frequency. The doubling in frequency present in ANN/SUM recordings
245 results from activation of nerve fibers responding to the depolarizing phase of the stimulus. There is a
246 half-cycle difference in latency of the depolarizing phase for rarefaction and condensation stimuli; when
247 both recordings are summed, the resulting waveform oscillates at twice the stimulus frequency. In this
248 case, there is also evidence of a compound action potential in the ANN/SUM recording, with a latency of
249 about 4 ms. The bottom middle and bottom right panels show the resulting FFT for each recording. Note
250 there is a peak at the stimulus frequency for the CM/DIFF and a peak at twice the stimulus frequency for
251 the ANN/SUM. In addition, higher order harmonics are sometimes present due to distortions in the hair
252 cell and neural signal transduction process (Forgues et al, 2014).

253

254

--- FIGURE 2 ---

255

256 Figure 2 shows amplitude growth functions for the CM/DIFF and ANN/SUM recordings for the same
257 subject (622-5R). The peaks of the FFT at the stimulus frequency for the CM/DIF recordings were used in
258 plotting the amplitude growth functions. This was similarly done for the peak at twice the stimulus
259 frequency for the ANN/SUM growth functions. As previously mentioned, we extracted threshold, slope,
260 and a suprathreshold amplitude. Note that this results in 12 variables extracted for the CM and 12

261 variables extracted for the ANN (4 frequencies x 3 variables), all of which were subjected to individual
262 LME analyses. The threshold is the lowest stimulus level that results in an ECoG response, measured in
263 dB HL. The slope represents the rate of change in amplitude as the stimulus level increases, calculated
264 using a linear regression, and measured in $\mu\text{V}/\text{dB}$. For the suprathreshold amplitude, we identified the
265 highest stimulus level that was used across all time points for a particular stimulus frequency. We then
266 extracted the corresponding electrocochleogram amplitudes for all those time points. For example, in
267 the case of subject 622-5R represented in Figure 2, the highest level used for the 250 Hz stimulation
268 frequency across all time points was 90 dB HL. The corresponding amplitude in the growth function for
269 that stimulus level was used in the longitudinal analysis. Similarly, amplitudes corresponding to a 100,
270 110-, and 110-dB HL stimulus levels for 500, 750, and 1000 Hz stimulation frequencies were used in the
271 analysis for this subject.

272

273 --- FIGURE 3 ---

274

275 Figure 3 shows example longitudinal thresholds, slopes and amplitudes for the same subject
276 represented in Figure 2. The top panels show raw values while the bottom panels show changes in
277 values over time. In this case, the subject showed some improvement in audiometric hearing over time;
278 this is likely due to resolution of middle ear fluid and resulting conductive hearing loss, as commonly
279 seen immediately post CI surgery. As more clearly seen in the bottom panels, the changes in ECoG
280 thresholds and amplitudes mirror changes in behavioral audiometric thresholds. Thresholds and
281 amplitudes are generally stable during periods of stable hearing. Thresholds and amplitudes worsen
282 with loss of hearing, and vice-versa.

283

284 **Stability of ECoG measures**

285

286 As previously mentioned, the primary question of interest was evaluating the stability of ECoG metrics
287 over time in the stable hearing group and the hearing loss group. Thus, the change in each ECoG metric
288 was calculated relative to baseline for each subject (e.g bottom panels of Figure 3). These metrics were
289 obtained for all subjects, and separate LME models for each ECoG metric at each frequency were
290 conducted to analyze whether longitudinal trends were statistically significant.

291

292 Table 3 summarizes the results of the LME models. For those with stable hearing, there are no changes
293 noted in CM/DIFF or ANN/SUM thresholds or amplitude over time for any frequencies (except for the
294 250 Hz CM/DIFF threshold). In contrast, there are changes in thresholds and amplitudes noted in most
295 cases for those with loss of hearing. As evidence by the β -values, amplitudes generally decreased ($\beta <$
296 0) and thresholds generally increased ($\beta > 0$) with loss of hearing. Additionally, though there was some
297 evidence of the slope becoming shallower for the hearing loss group, ($\beta < 0$), the slope metric was
298 generally not statistically significant.

299

300

--- TABLE 3 ---

301

302 **Comparisons of CM/DIFF and ANN/SUM losses**

303

304 It is evident from the previous analysis that both CM/DIFF and ANN/SUM metrics decline with declines
305 in audiometric hearing. It was also of interest to see if there are equal drops in both CM/DIFF and
306 ANN/SUM potentials, or if there is a greater decline in one potential compared to the other. If there is a
307 greater decline in one potential, it may shed more insight into the physiology of delayed hearing loss.

308

309 --- FIGURE 4 ---

310
311 Figure 4 plots changes in the CM/DIFF metric relative to the changes in ANN/SUM metric that occurs at
312 the time point where hearing loss was identified. The two metrics of interest were threshold and
313 amplitude, as those metrics were affected by loss of hearing. The slope of the ECoG amplitude growth
314 function was not analyzed here since it was not sensitive to loss of acoustic hearing.

315
316 For the threshold analysis, the difference in the CM/DIFF threshold at the time point of hearing loss and
317 the previous appt was calculated. The same calculation was performed for the ANN/SUM threshold.
318 These two differences were then plotted against one another. For the amplitude analysis, a ratio of the
319 CM/DIFF amplitude at loss of hearing relative to the previous appointment was calculated. The same
320 ratio calculation was performed for the ANN/SUM amplitudes. These two ratios were plotted against
321 one another.

322
323 Figure 4 left panel focuses on threshold changes. As summarized in Table 4, there is a significant
324 correlation between CM/DIFF threshold changes and ANN/SUM threshold changes. More importantly, a
325 paired t-test compared the CM/DIFF and ANN/SUM threshold change at time point of hearing loss and
326 showed that there were no differences in threshold changes. A similar result was found for the
327 amplitude changes, in that both CM/DIFF and ANN/SUM amplitudes have similar decrements after loss
328 of hearing.

329
330 --- TABLE 4 ---

331
332 **Correlations between Behavioral Audiogram, ECoG Slopes, ECoG Thresholds, and ECoG amplitudes**

333

334 As a secondary analysis, CM/DIFF, ANN/SUM, and behavioral audiometric thresholds from each
335 subject's latest test session were obtained. Figure 5 shows correlations between behavioral audiometric
336 thresholds and electrophysiologic thresholds. In general, electrophysiological thresholds are well
337 correlated with behavioral thresholds. In addition, 500 and 750 Hz CM/DIFF thresholds are closest to
338 behavioral thresholds. Note that for these correlational analyses, cases of no ECoG responses (as
339 indicated by the open symbols) were plotted as 120 dB HL but were excluded from correlational
340 analyses.

341

342 --- FIGURE 5 ---

343

344 Figure 6 shows correlations between behavioral audiometric thresholds and electrophysiologic slopes of
345 the ECoG amplitude growth functions. It was thought that those with better residual hearing would have
346 steeper slopes. In general, this was not the case, except for the 750 and 1000 Hz CM/DIFF growth slopes
347 and the 1000 Hz ANN/SUM growth slopes ($r = -0.407, -0.6654, \text{ and } -0.5302$, respectively, with $p < 0.01$ in
348 all three case). Note that for these correlational analyses, cases of no behavioral audiometric responses
349 (as indicated by the open symbols) were plotted as 120 dB HL but were excluded from correlational
350 analyses.

351

352 --- FIGURE 6 ---

353

354 Figure 7 shows correlations between behavioral audiometric thresholds and electrophysiologic
355 amplitudes obtained using the subject's C-level. It was thought that those with better residual hearing
356 would have higher ECoG amplitudes. Generally speaking, there were trends of higher ECoG amplitudes

357 for those with better residual hearing (lower audiometric thresholds). As summarized in Table 5, these
358 trends were statistically significant or borderline statistically significant for the CM/DIFF potentials at all
359 tested frequencies. These trends were statistically significant for the 500 Hz and 1000 Hz ANN/SUM
360 potentials.

361

362 --- FIGURE 7 ---

363

364 --- TABLE 5 ---

365

366 The slopes of the CM/DIFF and ANN/SUM amplitude growth functions were plotted against one another
367 to ascertain if there were correlations between both and to understand if one potential grows faster
368 than the other. From Figure 8, it does appear that both metrics are correlated. More importantly is that
369 the CM/DIFF grows more quickly as the stimulation level increases, as evidenced by the steeper slopes
370 on the y-axis of Figure 8.

371

372 --- FIGURE 8 ---

373

374

375 **DISCUSSION**

376 Past studies of electrocochleography in CI users have focused on its application during CI surgery (Bester
377 et al, 2022; Lenarz et al, 2022), to predict post-operative speech understanding and behavioral
378 audiometric thresholds (Abbas et al, 2017; Koka et al, 2017, Fontenot et al, 2019), and to guide
379 programming of the hearing aid component of the EAS sound processor (Agrawal et al, 2020). The
380 current study provides a new application of ECoG, that is, to be used as an objective measure of

381 longitudinal peripheral auditory function in EAS CI users. The stability of both CM and ANN amplitudes
382 seen in our Nucleus CI users is consistent with the intertest and intratest reliability of ECoG measures in
383 normal hearing and sensorineural hearing loss populations (Bergholtz et al, 1976; Densert et al, 1994;
384 Mori et al, 1981; Park & Ferraro, 1999). Thus, the increase in ECoG thresholds and decrease in ECoG
385 amplitudes in those with delayed hearing loss is likely clinically meaningful. The slope of the ECoG
386 amplitude growth function was not a meaningful metric, as slopes were stable across repeated test
387 sessions for both subjects with stable hearing and subjects with delayed loss of hearing.

388
389 One limitation of ECoG studies in general is that the difference / summation technique to separate out
390 hair cell / neural potentials is not perfect. That is, it is very possible that there is still a neural
391 component in the CM/DIFF traces that hasn't been isolated out (e.g. Forgues et al 2014; Abbas et al,
392 2017). The contamination of the ANN/SUM responses by the CM can be seen at stimulus levels 30-40 dB
393 above CM threshold (Forgues et al 2014). Thus, for subjects with particularly large dynamic ranges in
394 their ECoG amplitude growth functions, some of the suprathreshold amplitudes may be affected by this
395 contamination.

396
397 From a clinical perspective, both CM and ANN potentials are equally affected with loss of hearing, as
398 shown by Figure 4 and Table 4. However, the threshold measures may be more a more reliable indicator
399 of loss of hearing as they are not as affected by incomplete separation of CM and ANN potentials using
400 the difference and summation techniques (Forgues et al, 2014). Regardless, the similar impact on CM
401 and ANN thresholds and slopes implies a common underlying reason of delayed hearing loss, though
402 there are many probable etiologies that are debatable. Eshraghi et al. (2013) observed outer hair cell
403 loss in their animal models of CI, which at first glance appears consistent with loss of CM and ANN
404 potentials in our delayed-hearing loss population. However, their animal CI protocol involved extensive

405 electrode-induced cochlear trauma such that shifts in both low- and high-frequency hearing were
406 observed. These conditions may not necessarily reflect our low-frequency hearing preservation patients.

407

408 Animal studies have shown that the ANN/SUM potential is sensitive to changes in endocochlear
409 potentials (Lichtenhan et al, 2017). Compromised endocochlear potentials have been implicated in
410 delayed hearing loss, at least in the high-frequency region of the cochlea where the CI electrode lies
411 (Tanaka et al. 2014; Reiss et al. 2015). Alternatively, our previous human electrophysiological findings
412 based on complex electrode impedance measures, as well as a post-mortem human EAS CI study,
413 suggest intracochlear fibrosis as a contributor to delayed hearing loss (Quesnel et al, 2016; Tejani et al,
414 2022).

415

416 In general, animal histology has suggested many possible etiologies, such as compromised endocochlear
417 potentials (Tanaka et al. 2014; Reiss et al. 2015), cochlear neuropathy/synaptopathy (Li et al. 2020), and
418 excitotoxicity (Kopelovich et al. 2015). A common theme is that these studies in general do not implicate
419 hair cell / neural damage / pre-synaptic / post-synaptic damage (O'Leary et al. 2013; Tanaka et al. 2014;
420 Reiss et al. 2015; Quesnel et al. 2016). Without post-mortem histology, one cannot definitely prove the
421 underlying causes of delayed hearing loss in humans post-CI (e.g. Quesnel et al, 2016). This limitation
422 thus makes electrophysiology, including electrocochleography, a valuable tool to investigate loss of
423 hearing in human CI users (e.g. Scheperle et, 2017; Tejani et al, 2021, 2022).

424

425 Our secondary analysis of correlations with audiometric thresholds shows that regardless of audiometric
426 frequency, there is a strong correlation between ECoG thresholds and audiometric thresholds. This is
427 despite the fact that a combination of electrode arrays was used, with some electrodes having partial
428 insertions. These strong correlations are consistent with past studies conducted by our institution

429 (Abbas et al, 2018; Kim et al, 2018) and others (Koka et al, 2017; Agarwal et al, 2021). In contrast, our
430 slope metrics were generally not well correlated with behavioral audiometry. Additionally, subjects with
431 greater residual hearing also tended to have higher ECoG amplitudes, which is consistent with
432 correlations between ECoG “total-response” amplitudes and behavioral audiometry (Fitzpatrick et al,
433 2014). This was especially the case for CM/DIFF potentials. In the case of the ANN/SUM amplitudes,
434 these correlations were not statistically significant in some cases. The lack of correlation may stem from
435 the lower spread of ANN/SUM amplitudes since these potentials are generally small.

436
437 Our present study provides a new application of post-operative ECoG in monitoring residual hearing and
438 understanding the pathophysiology of delayed hearing loss. In a future study, we will explore further
439 applications of post-operative ECoG, including the relationship between post-operative ECoG and
440 speech perception, as most data in the literature focuses interoperative ECoG at time of surgery and
441 correlating that with outcome measures (Fontenot et al, 2019, Canfarotta et al, 2021; Walia et al, 2022).
442 In addition, while our measures were conducted using in-house custom-built equipment, cochlear
443 implant companies are also designing and implementing hardware and software adaptations so that
444 their own systems can be used for ECoG recordings. Thus, it is foreseeable that both intraoperative and
445 post-operative ECoG recordings can be integrated into clinical practice.

REFERENCES

- 446
447
448 Abbas PJ, Tejani VD, Scheperle RA, Brown CJ (2017). Using Neural Response Telemetry to Monitor
449 Physiological Responses to Acoustic Stimulation in Hybrid Cochlear Implant Users. *Ear Hear.*
450 38(4):409-425. <https://doi.org/10.1097/AUD.0000000000000400>
451
452 Adunka O, Gstoettner W, Hambek M, Unkelbach MH, Radeloff A, Kiefer J (2004) Preservation of basal
453 inner ear structures in cochlear implantation. *ORL* 66:306-312.
454 <https://doi.org/10.1159/000081887>.
455
456 Adunka OF, Pillsbury HC, Buchman CA (2010). Minimizing intracochlear trauma during cochlear
457 implantation. *Adv Otorhinolaryngol.* 67:96-107. <https://doi.org/10.1159/000262601>.
458
459 Aran J-M & Charlet de Sauvage R (1976). Clinical value of cochlear microphonic recordings. In: Ruben RJ,
460 Elberling C, Salomon G. (Eds.), *Electrocochleography*. University Park Press, Baltimore, MD, pp.
461 55e65.
462
463 Agrawal S, Coulthurst S, Nachman A, Koka K, & Murray M. (2021, ePub ahead of print). Acoustic
464 component programming in children with cochlear implants using electrocochleography.
465 *International journal of audiology*, 1–8. <https://doi.org/10.1080/14992027.2021.1917779>
466
467 Bester C, Collins A, Razmovski T, Weder S, Briggs RJ, Wei B, Zakaria AF, Gerard JM, Mitchell-Innes A,
468 Tykocinski M, Kennedy R, Iseli C, Dahm M, Ellul S, O'Leary S. (2021). Electrocochleography
469 triggered intervention successfully preserves residual hearing during cochlear implantation:
470 Results of a randomised clinical trial. *Hearing research*, 108353. Advance online publication.
471 <https://doi.org/10.1016/j.heares.2021.108353>
472
473 Bergholtz LM, Hooper RE, & Mehta DC. (1976). Test-retest reliability in clinical electrocochleography.
474 *The Annals of otology, rhinology, and laryngology*, 85(5 Pt.1), 679–685.
475 <https://doi.org/10.1177/000348947608500519>.
476
477 Brockmeier SJ, Peterreins M, Lorens A, Vermeire K, Helbig S, Anderson I, Skarzynski H, Van de Heyning P,
478 Gstoettner W, Kiefer J (2010) Music perception in electric acoustic stimulation users as assessed
479 by the Mu.S.I.C. test. *Adv Otorhinolaryngol* 67:70–80. <https://doi.org/10.1159/000262598>.
480
481 Choi C-H, Oghalai JS (2005). Predicting the effect of post-implant cochlear fibrosis on residual hearing.
482 *Hear Res.* 205(1-2):193-200. <https://doi.org/10.1016/j.heares.2005.03.018>.
483
484 Canfarotta, M. W., O'Connell, B. P., Giardina, C. K., Buss, E., Brown, K. D., Dillon, M. T., Rooth, M. A.,
485 Pillsbury, H. C., Buchman, C. A., Adunka, O. F., & Fitzpatrick, D. C. (2021). Relationship Between
486 Electrocochleography, Angular Insertion Depth, and Cochlear Implant Speech Perception
487 Outcomes. *Ear and hearing*, 42(4), 941–948. <https://doi.org/10.1097/AUD.0000000000000985>.
488
489 Densert B, Arlinger S, Sass K, & Hergils L. (1994). Reproducibility of the electric response components in
490 clinical electrocochleography. *Audiology*: 33(5), 254–263.
491 <https://doi.org/10.3109/00206099409071885>
492

- 493 Dunn CC, Perreau A, Gantz B, Tyler RS (2010) Benefits of localization and speech perception with
494 multiple noise sources in listeners with a short-electrode cochlear implant. *J Am Acad Audiol*
495 21(1):44–51. <https://doi.org/10.3766/jaaa.21.1.6>.
496
- 497 Eggermont JJ (2017). Ups and Downs in 75 Years of Electrocochleography. *Front Syst Neurosci.* 11:2.
498 <https://doi.org/10.3389/fnsys.2017.00002>.
499
- 500 Eshraghi AA, Gupta C, Van De Water TR, Bohorquez JE, Garnham C, Bas E, Talamo VM (2013). Molecular
501 mechanisms involved in cochlear implantation trauma and the protection of hearing and
502 auditory sensory cells by inhibition of c-Jun-N-terminal kinase signaling. *Laryngoscope*, 123
503 Suppl 1, S1–S14. <https://doi.org/10.1002/lary.23902>
504
- 505 Fitzpatrick DC, Campbell AP, Choudhury B, Dillon MT, Forgues M, Buchman CA, Adunka OF. (2014).
506 Round window electrocochleography just before cochlear implantation: relationship to word
507 recognition outcomes in adults. *Otology & Neurotology*. 35(1), 64–71.
508 <https://doi.org/10.1097/MAO.0000000000000219>
509
- 510 Foggia MJ, Quevedo RV, Hansen MR (2019). Intracochlear fibrosis and the foreign body response to
511 cochlear implant biomaterials. *Laryngoscope Investig Otolaryngol.* 4(6):678-683.
512 <https://doi.org/10.1002/lio2.329>.
513
- 514 Forgues M, Koehn HA, Dunnon AK, Pulver SH, Buchman CA, Adunka OF, Fitzpatrick DC (2014).
515 Distinguishing hair cell from neural potentials recorded at the round window. *J Neurophysiol.*
516 111(3):580-593. <https://doi.org/10.1152/jn.00446.2013>.
517
- 518 Fontenot TE, Giardina CK, Dillon M, Rooth MA, Teagle HF, Park LR, Brown KD, Adunka OF, Buchman CA,
519 Pillsbury HC, Fitzpatrick DC (2019). Residual Cochlear Function in Adults and Children Receiving
520 Cochlear Implants: Correlations With Speech Perception Outcomes. *Ear Hear.* 40(3):577-591.
521 <https://doi.org/10.1097/AUD.0000000000000630>.
522
- 523 Gantz BJ, Turner CW (2003). Combining acoustic and electrical hearing. *Laryngoscope.* 113: 1726-1730.
524 <http://dx.doi.org/10.1097/00005537-200310000-00012>.
525
- 526 Gantz BJ, Dunn CC, Oleson J, Hansen MR (2017). Acoustic plus electric speech processing: Long-term
527 results. *Laryngoscope.* <https://doi.org/10.1002/lary.26669>
528
- 529 Gifford RH, Dorman MF , Spahr AJ , Bacon SP, Skarzynski H, Lorens A (2008) Hearing preservation
530 surgery: psychophysical estimates of cochlear damage in recipients of a short electrode array. *J*
531 *Acoust Soc Am* 124(4):2164–2173. <https://doi.org/10.1121/1.2967842>.
532
- 533 Gifford RH, Dorman MF , Brown CA (2010) Psychophysical properties of low-frequency hearing:
534 implications for perceiving speech and music via electric and acoustic stimulation. *Adv*
535 *Otorhinolaryngol* 67:51–60. <https://doi.org/10.1159/000262596>.
536
- 537 Gfeller KE, Olszewski C, Turner C, Gantz B, Oleson J (2006) Music perception with cochlear implants and
538 residual hearing. *Audiol Neurootol* 11(Suppl 1):12–15. <https://doi.org/10.1159/000095608>.
539

- 540 Golub JS, Won JH, Drennan WR, Worman TD, Rubinstein JT (2012). Spectral and temporal measures in
541 hybrid cochlear implant users: on the mechanism of electroacoustic hearing benefits. *Otol*
542 *Neurotol.* 33(2):147-153. <https://doi.org/10.1097/MAO.0b013e318241b6d3>.
543
- 544 Henry KR (1995). Auditory nerve neurophonic recorded from the round window of the Mongolian gerbil.
545 *Hear Res.* 90 (1-2), 176-184. [https://doi.org/10.1016/0378-5955\(95\)00162-6](https://doi.org/10.1016/0378-5955(95)00162-6).
546
- 547 Kim JS, Tejani VD, Abbas PJ, Brown CJ (2018). Postoperative Electrocochleography from Hybrid Cochlear
548 Implant users: An Alternative Analysis Procedure. *Hear Res.* 370:304-315.
549 <https://doi.org/10.1016/j.heares.2018.10.016>.
550
- 551 Koka K, Saoji AA, Litvak LM (2017). Electrocochleography in Cochlear Implant Recipients With Residual
552 Hearing: Comparison With Audiometric Thresholds. *Ear Hear.* 38(3):e161-e167. doi:
553 <https://doi.org/10.1097/AUD.0000000000000385>.
554
- 555 Lenarz T, Buechner A, Gantz BJ, Hansen MR, Tejani VD, Labadie R, O'Connell B, Buchman CA, Valenzuela
556 CV, Adunka OF, Harris MS, Riggs WJ, Fitzpatrick DC, Koka K (2022). Relationship between
557 Intraoperative Electrocochleography and Hearing Preservation. *Otology and Neurotology.*
558 43(1):e72-e78. <https://doi.org/10.1097/mao.00000000000003403>.
559
- 560 Lenarz T, James C, Cuda D, Fitzgerald O'Connor A, Frachet B, Frijns JH, Klenzner T, Laszig R, Manrique M,
561 Marx M, Merkus P, Mylanus EA, Offeciers E, Pesch J, Ramos-Macias A, Robier A, Sterkers O, Uziel
562 A. (2013). European multi-centre study of the Nucleus Hybrid L24 cochlear implant. *Int J Audiol.*
563 52(12):838-48. <https://doi.org/10.3109/14992027.2013.802032>.
564
- 565 Li Q, Lu T, Zhang C, Hansen MR, Li S (2020). Electrical stimulation induces synaptic changes in the
566 peripheral auditory system. *J Comp Neurol.* 528(6):893-905. <https://doi.org/10.1002/cne.24802>.
567
- 568 Lichtenhan JT, Cooper NP, Guinan Jr. JJ (2013). A new auditory threshold estimation technique for low
569 frequencies: Proof of concept. *Ear Hear.* 34(1): 42-51.
570 <https://doi.org/10.1097/AUD.0b013e31825f9bd3>.
571
- 572 Lichtenhan JT, Lee C, Dubaybo F, Wenrich KA, & Wilson US. (2017). The Auditory Nerve Overlapped
573 Waveform (ANOW) Detects Small Endolymphatic Manipulations That May Go Undetected by
574 Conventional Measurements. *Frontiers in neuroscience*, 11, 405.
575 <https://doi.org/10.3389/fnins.2017.00405>
576
- 577 Mori N, Matsunaga T, & Asai H. (1981). Intertest reliability in non-invasive electrocochleography.
578 *Audiology:* 20(4), 290–299. <https://doi.org/10.3109/00206098109072702>
579
- 580 O'Leary SJ, Monksfield P, Kel G, Connolly T, Souter MA, Chang A, Marovic P, O'Leary JS, Richardson R,
581 Eastwood H (2013). Relations between cochlear histopathology and hearing loss in experimental
582 cochlear implantation. *Hear Res.* 298: 27-35. <https://doi.org/10.1016/j.heares.2013.01.012>.
583
- 584 Pappa AK, Hutson KA, Scott WC, Wilson JD, Fox KE, Masood MM, Giardina CK, Pulver SH, Grana GD,
585 Askew C, Fitzpatrick DC (2019). Hair cell and neural contributions to the cochlear summing
586 potential. *J Neurophysiol.* 121(6):2163-2180. <https://doi.org/10.1152/jn.00006.2019>
587

- 588 Park, D. L., & Ferraro, J. A. (1999). Intrasubject Test-Retest Reliability in Tympanic Electrocochleography.
589 *Journal of the American Academy of Audiology*, 10(3): 160-165.
590
- 591 Pillsbury HC 3rd, Dillon MT, Buchman CA, Staecker H, Prentiss SM, Ruckenstein MJ, Bigelow DC, Telischi
592 FF, Martinez DM, Runge CL, Friedland DR, Blevins NH, Larky JB, Alexiades G, Kaylie DM, Roland
593 PS, Miyamoto RT, Backous DD, Warren FM, El-Kashlan HK, Slager HK, Reyes C, Racey AI, Adunka
594 OF (2018). Multicenter US Clinical Trial With an Electric-Acoustic Stimulation (EAS) System in
595 Adults: Final Outcomes. *Otol Neurotol*. 39(3):299-305.
596 <https://doi.org/10.1097/MAO.0000000000001691>.
597
- 598 Quesnel AM, Nakajima HH, Rosowski JJ, Hansen MR, Gantz BJ, Nadol JB Jr (2016). Delayed loss of
599 hearing after hearing preservation cochlear implantation: Human temporal bone pathology and
600 implications for etiology. *Hear Res*. 333:225-234. <https://doi.org/10.1016/j.heares.2015.08.018>
601
- 602 Rauch SD, Halpin CF, Antonelli PJ, Babu S, Carey JP, Gantz BJ, Goebel JA, Hammerschlag PE, Harris JP,
603 Isaacson B, Lee D, Linstrom CJ, Parnes LS, Shi H, Slattery WH, Telian SA, Vrabc JT, Reda DJ
604 (2011). Oral vs intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing
605 loss: a randomized trial. *JAMA*. 305(20):2071-2079. <https://doi.org/10.1001/jama.2011.679>.
606
- 607 Reiss LA, Stark G, Nguyen-Huynh AT, Spear KA, Zhang H, Tanaka C, Li H (2015). Morphological correlates
608 of hearing loss after cochlear implantation and electro-acoustic stimulation in a hearing-
609 impaired Guinea pig model. *Hear Res*. 327:163-174.
610 <https://doi.org/10.1016/j.heares.2015.06.007>
611
- 612 Roland JT Jr, Gantz BJ, Waltzman SB, Parkinson AJ; Multicenter Clinical Trial Group (2016). United States
613 multicenter clinical trial of the cochlear nucleus hybrid implant system. *Laryngoscope*.
614 126(1):175-81. <https://doi.org/10.1002/lary.25451>.
615
- 616 Roland JT Jr, Gantz BJ, Waltzman SB, Parkinson AJ (2018). Long-term outcomes of cochlear implantation
617 in patients with high-frequency hearing loss. *Laryngoscope*. 128(8):1939-1945.
618 <https://doi.org/10.1002/lary.27073>.
619
- 620 Scheperle RA, Tejani VD, Omtvedt JK, Brown CJ, Abbas PJ, Hansen MR, Gantz BJ, Oleson JJ, Ozanne MV.
621 (2017). Delayed changes in auditory status in cochlear implant users with preserved acoustic
622 hearing. *Hear Res*. 350:45-57. <https://doi.org/10.1016/j.heares.2017.04.005>.
623
- 624 Tanaka C, Nguyen-Huynh A, Loera K, Stark G, Reiss L (2014). Factors associated with hearing loss in a
625 normal-hearing guinea pig model of Hybrid cochlear implants. *Hear Res*. 316:82-93.
626 <https://doi.org/10.1016/j.heares.2014.07.011>.
627
- 628 Tejani VD, Abbas PJ, Brown CJ, Woo J (2019). An improved method of obtaining electrocochleography
629 recordings from Nucleus Hybrid cochlear implant users. *Hear Res*. 373:113-120.
630 <https://doi.org/10.1016/j.heares.2019.01.002>.
631
- 632 Tejani VD, Brown CJ (2020). Speech masking release in Hybrid cochlear implant users: Roles of spectral
633 and temporal cues in electric-acoustic hearing. *J Acoust Soc Am*. 147(5):3667.
634 <http://dx.doi.org/10.1121/10.0001304>.
635

- 636 Tejani VD, Kim J-S, Oleson JJ, Abbas PJ, Brown CJ, Hansen MR, Gantz BJ (2021). Residual Hair Cell
637 Responses in Electric-Acoustic Stimulation Cochlear Implant Users with Complete Loss of
638 Acoustic Hearing After Implantation. *Journal of the Association for Research in Otolaryngology*.
639 22(2), 161-176. <https://doi.org/10.1007/s10162-021-00785-4>.
640
- 641 Tejani VD, Yang H, Kim J-S, Hernandez H, Oleson JJ, Hansen MR, Gantz BJ, Abbas PJ, Brown CJ (2022).
642 Access and Polarization Electrode Impedance Changes in Relation to Delayed Loss of Acoustic
643 Hearing in Electric-Acoustic Stimulation Cochlear Implant Users. *Journal of the Association for
644 Research in Otolaryngology*. 23, 95–118. <https://doi.org/10.1007/s10162-021-00809-z>.
645
- 646 Turner CW, Gantz BJ, Vidal C, Behrens A, Henry BA (2004). Speech recognition in noise for cochlear
647 implant listeners: Benefits of residual acoustic hearing. *J Acoust Soc Am*. 115(4):1729-1735.
648 <http://dx.doi.org/10.1121/1.1687425>.
649
- 650 van Abel KM, Dunn CC, Sladen DP, Oleson JJ, Beatty CW, Neff BA, Hansen M, Gantz BJ, Driscoll CLW
651 (2015) Hearing preservation among patients undergoing cochlear implantation. *Otol Neurotol*.
652 36:416-421. <https://doi.org/10.1097/MAO.0000000000000703>.
653
- 654 von Ilberg C, Kiefer J, Tillein J, Pfenningdorff T, Hartmann R, Stürzebecher E, Klinke R. (1999). Electric-
655 acoustic stimulation of the auditory system. New technology for severe hearing loss. *ORL J
656 Otorhinolaryngol Relat Spec*. 61(6):334-340. <https://doi.org/10.1159/000027695>.
657
- 658 Walia, A., Shew, M. A., Kallogjeri, D., Wick, C. C., Durakovic, N., Lefler, S. M., Ortmann, A. J., Herzog, J. A.,
659 & Buchman, C. A. (2022). Electrocochleography and cognition are important predictors of
660 speech perception outcomes in noise for cochlear implant recipients. *Scientific reports*, 12(1),
661 3083. <https://doi.org/10.1038/s41598-022-07175-7>




Figure 1: Example ECoG recording for subject 622-5R in response to a 500 Hz tone burst presented at 105 dB HL. The 12m indicates he was seen at his 12-month post CI appointment. Top left panel shows the responses to rarefaction and condensation stimuli. Top middle and right panels show the resulting CM/DIFF and ANN/SUM recordings. The bottom panels represent the resultant FFT analyses of the CM/DIFF and ANN/SUM recordings. Significant FFT peaks (including higher order harmonics) are marked by the black filled circles, with the corresponding FFT amplitudes indicated in the top right of the FFT plots.




Figure 2: Longitudinal Audiograms and ECoG amplitude growth functions for Subject 622-5R. The left panel shows the behavioral audiograms. The top row of mini-panels show CM/DIFF amplitude growth functions while the bottom row of mini-panels show ANN/SUM amplitude growth functions for the four stimulus frequencies.




Figure 3: Longitudinal audiometric thresholds, ECoG thresholds, slopes, and amplitudes for subject 622-5R. The top row shows the raw values while the bottom row shows changes in these metrics relative to the baseline appointment conducted at 0.25 months post CI activation. For the ECoG metrics, closed symbols represent the CM/DIFF recordings while the open symbols represent the ANN/SUM recordings.




Figure 4: Comparisons of CM/DIFF and ANN/SUM changes after loss of hearing. The dotted line indicates equal changes in threshold (left panel) and amplitude (right panel). For the left panel, positive numbers indicate an increased (worsened) threshold with loss of hearing. For the right panel, a ratio < 1 indicates a decreased (worsened) amplitude with loss of hearing.




Figure 5: Correlations between ECoG and behavioral thresholds for 250, 500, 750, and 1000 Hz stimuli. The dotted line indicates equal CM/DIFF and ANN/SUM thresholds. Note that cases of no ECoG responses are indicated by the open symbols and are not included in correlational analyses.




Figure 6: Correlations between ECoG slope and behavioral thresholds for 250, 500, 750, and 1000 Hz stimuli. Note that in the bottom plots, cases of no behavioral responses are indicated by the open symbols and are not included in correlational analyses.




Figure 7: Correlations between ECoG amplitudes and behavioral thresholds for 250, 500, 750, and 1000 Hz stimuli. Note that in the bottom plots, cases of no behavioral responses are indicated by the open symbols and are not included in correlational analyses. Subject S12RW-6R was excluded from the correlational analysis as he was a clear outlier with unusually large (100 μV) amplitudes.




Figure 8: Correlations between CM/DIFF and ANN/SUM amplitude growth function slopes for 250, 500, 750, and 1000 Hz stimuli.

Table 1: Subject Demographics

Subject ID	Ear	Pre-op PTA (125 - 500 Hz)	Array	Implant Date	ECoG monitoring?	Full or Partial Insertion?	Time points tested post activation (months)	250 Hz Category	500 Hz Category	750 Hz Category	1000 Hz Category
A8	R	18	S8	05/2006	N	Full	156, 169	S	S	S	S
L3R	R	45	L24	5/2010	N	Full	109, 122	HL	HL	S	S
T10L	L	27	S12	12/2010	N	Full	100, 113	S	S	S	S
L13L	L	52	L24	11/2012	N	Full	72,81,85	S	S	S	S
T12L	L	20	S12	11/2013	N	Full	54, 72	S	HL	S	S
L17L	L	37	L24	11/2013	N	Full	72, 84	S	S	S	S
L25L	L	42	L24	8/2014	N	Full	55, 60	S	S	S	S
S35L	L	48	422	9/2014	N	Full	60, 72	S	S	S	S
S44R	R	58	422	2/2015	N	Full	37, 49	S	S	HL	S
S36R	R	55	422	2/2015	N	Full	36, 48	S	S	S	S
L33L	L	25	L24	5/2015	N	Full	49, 61	S	S	S	S
L44R	R	30	L24	12/2015	N	Full	36, 48	S	HL	HL	S
L43R	R	43	L24	6/2016	N	Full	36, 48	S	S	HL	S
S12RW-3L	L	21	S12RW	12/2016	N	Full	6, 12	S	S	S	S
L66R	R	40	L24	4/2017	N	Full	12, 22	HL	S	S	S
L67R	R	47	L24	5/2017	N	Full	23, 38	S	S	S	S
L77R	R	35	L24	8/2017	N	Full	26, 35	HL	HL	HL	HL
L80R	R	22	L24	5/2018	Y	Full	0.5, 1, 3	S	S	S	S
L81R	R	27	L24	6/2018	Y	Full	0.5, 1, 3, 6	HL	HL	HL	HL
S12RW-6R	R	33	S12RW	10/2018	Y	Full	0.5, 1, 3, 6, 12	S	HL	HL	HL
L86R	R	41	L24	1/2019	Y	Full	0.5, 1, 3, 6	S	S	S	S
522-11L	L	37	CI522	7/2019	Y	Full	0.5, 1	S	S	S	S
622-2R	R	63	CI622	11/2019	Y	Full	0.5, 1, 3	S	S	S	S
622-3R	R	47	CI622	11/2019	Y	Full	0.5, 1, 3	S	S	S	S
624-20R	R	35	CI624	1/2020	Y	Full	0.5, 1, 3, 6, 12	HL	HL	HL	HL
622-5R	R	43	CI622	1/2020	Y	3 Electrodes Extracochlear	0.5, 1, 6, 12	S	S	S	S
624-1R	R	46	CI624	5/2020	Y	Full	0.5, 1, 3, 9	HL	HL	HL	HL
624-2R	R	60	CI624	5/2020	Y	Full	0.5, 1, 3, 6	HL	HL	HL	HL
624-4R	R	65	CI624	6/2020	Y	Full	0.5, 1, 3, 8	HL	HL	HL	HL
624-6R	R	53	CI624	6/2020	Y	Full	0.5, 1, 3, 6	S	S	S	S

624-8R	R	43	CI624	7/2020	Y	Full	0.5, 1, 7	S	S	S	S
624-9L	L	55	CI624	7/2020	Y	Full	0.5, 1, 3, 6	S	S	S	S
624-11R	R	43	CI624	8/2020	Y	Full	0.5, 1	S	S	S	S
624-12L	L	35	CI624	09/20	Y	Full	0.5, 1, 3, 12	HL	HL	S	S
624-13L	L	30	CI624	10/2020	Y	Full	0.5, 1, 3, 8	HL	HL	HL	HL
624-15R	R	52	CI624	11/2020	Y	Full	0.5, 1	S	S	S	S
624-16L	L	62	CI624	12/2020	Y	Full	0.5, 1, 3	HL	HL	S	S
624-18L	L	27	CI624	12/2020	Y	Full	0.5, 1, 3	S	HL	S	S
624-19R	R	20	CI624	12/2020	Y	3 Electrodes Extracochlear	0.5, 1	S	S	HL	S
624-21L	L	53	CI624	3/2021	Y	Full	0.5, 1, 3, 6	S	S	S	S

PAPER IN REVIEW

Array	Number of Electrodes	Active Array Length (mm)	Insertion Depth (mm)
S8 Hybrid *	6	4.05	10
S12 Hybrid *	10	5.7	10
S12RW Hybrid *	10	7.5	12
L24 Hybrid †	22	14.35	16
422/522/622 (Slim Lateral Wall) §	22	19.1	20-25
624 (Slim 20) §	22	19.1	20

* Investigational Device
† Initially Investigational, but now Commercially Available Device
§ Commercially Available

Table 3: Results of LME analysis. P-values were adjusted using a False Discovery Rate. Italicized numbers indicate results that are statistically significant.

Dependent variable	Stable Hearing			Hearing Loss		
	β	Statistics	p_{FDR}	β	Statistics	p_{FDR}
CM/DIFF Amplitude 250 Hz	0.059	t(81)=0.90, p=0.370	0.241	<i>-0.310</i>	<i>t(25)=-2.73, p=0.012</i>	<i>0.016</i>
CM/DIFF Amplitude 500 Hz	0.041	t(77)=0.54, p=0.591	0.318	<i>-0.399</i>	<i>t(34)=-2.10, p=0.043</i>	<i>0.049</i>
CM/DIFF Amplitude 750 Hz	0.266	t(73)=0.95, p=0.346	0.241	<i>-0.841</i>	<i>t(35)=-3.66, p=0.001</i>	<i>0.002</i>
CM/DIFF Amplitude 1000 Hz	0.117	t(79)=1.49, p=0.139	0.130	<i>-1.683</i>	<i>t(26)=-3.78, p=0.001</i>	<i>0.002</i>
CM/DIFF Slope 250 Hz	0.001	t(71)=0.33, p=0.743	0.384	-0.003	t(18)=-1.19, p=0.251	0.187
CM/DIFF Slope 500 Hz	0.007	t(62)=1.54, p=0.130	0.127	-0.005	t(27)=-1.48, p=0.150	0.130
CM/DIFF Slope 750 Hz	0.003	t(63)=0.32, p=0.749	0.384	0.015	t(29)=1.17, p=0.251	0.187
CM/DIFF Slope 1000 Hz	0.002	t(63)=1.46, p=0.149	0.130	<i>0.050</i>	<i>t(25)=2.35, p=0.027</i>	<i>0.033</i>
CM/DIFF Threshold 250 Hz	<i>-0.600</i>	<i>t(78)=-3.60, p=0.001</i>	0.002	2.491	t(22)=3.26, p=0.004	0.007
CM/DIFF Threshold 500 Hz	-0.004	t(74)=-0.03, p=0.977	0.447	2.509	t(34)=4.26, p=0.000	0.001
CM/DIFF Threshold 750 Hz	-0.002	t(70)=-0.00, p=0.996	0.447	1.265	t(35)=2.39, p=0.022	0.028
CM/DIFF Threshold 1000 Hz	-0.111	t(76)=-0.66, p=0.511	0.298	1.992	t(25)=4.17, p=0.000	0.002
ANN/SUM Amplitude 250 Hz	0.015	t(81)=1.68, p=0.097	0.100	<i>-0.124</i>	<i>t(25)=-3.14, p=0.004</i>	<i>0.008</i>
ANN/SUM Amplitude 500 Hz	0.009	t(77)=0.82, p=0.417	0.260	<i>-0.074</i>	<i>t(34)=-2.94, p=0.006</i>	<i>0.009</i>
ANN/SUM Amplitude 750 Hz	-0.002	t(73)=-0.21, p=0.837	0.410	<i>-0.100</i>	<i>t(35)=-2.94, p=0.006</i>	<i>0.009</i>
ANN/SUM Amplitude 1000 Hz	-0.001	t(79)=-0.08, p=0.935	0.447	<i>-0.196</i>	<i>t(26)=-4.91, p=0.000</i>	<i>0.001</i>
ANN/SUM Slope 250 Hz	0.001	t(63)=0.81, p=0.423	0.260	-0.001	t(15)=-0.79, p=0.441	0.264
ANN/SUM Slope 500 Hz	0.004	t(49)=1.16, p=0.251	0.187	0.001	t(17)=1.87, p=0.079	0.085
ANN/SUM Slope 750 Hz	0.001	t(32)=0.57, p=0.574	0.317	0.013	t(16)=0.95, p=0.357	0.241
ANN/SUM Slope 1000 Hz	<i>-0.004</i>	<i>t(22)=-3.80, p=0.001</i>	<i>0.002</i>	<i>0.022</i>	<i>t(13)=4.49, p=0.001</i>	<i>0.002</i>
ANN/SUM Threshold 250 Hz	-0.054	t(79)=-0.28, p=0.780	0.391	0.630	t(17)=0.93, p=0.365	0.241
ANN/SUM Threshold 500 Hz	-0.081	t(64)=-0.60, p=0.548	<i>0.311</i>	2.559	<i>t(24)=4.72, p=0.000</i>	<i>0.001</i>
ANN/SUM Threshold 750 Hz	-0.003	t(43)=-0.01, p=0.988	<i>0.447</i>	1.756	<i>t(28)=3.19, p=0.003</i>	<i>0.007</i>
ANN/SUM Threshold 1000 Hz	-0.395	t(30)=-1.36, p=0.185	<i>0.153</i>	1.443	<i>t(20)=2.82, p=0.011</i>	<i>0.015</i>

Table 4: Comparisons of CM/DIFF and ANN/SUM changes after loss of hearing. Italicized numbers indicate results that are statistically significant

Frequency (Hz)	Threshold Changes						Amplitude Changes					
	Correlation			t-test			Correlation			t-test		
	<i>n</i>	<i>r</i>	<i>p</i>	<i>t</i>	<i>df</i>	<i>p</i>	<i>n</i>	<i>r</i>	<i>p</i>	<i>t</i>	<i>df</i>	<i>P</i>
250	5	0.883	<i>0.024</i>	-0.612	4	0.573	3	0.974	<i>0.073</i>	-0.384	2	0.738
500	8	0.892	<i>0.001</i>	-1.843	7	0.108	6	0.861	<i>0.014</i>	0.183	5	0.862
750	10	0.886	<i>0.000</i>	0.176	9	0.864	6	0.79	<i>0.031</i>	-0.41	5	0.699
1000	4	0.93	<i>0.035</i>	-1.414	3	0.252	4	0.969	<i>0.015</i>	0.338	3	0.758

Table 5: Correlations between behavioral audiograms and suprathreshold ECoG amplitudes

Frequency (Hz)	Correlation		
	<i>n</i>	<i>r</i>	<i>p</i>
250 Hz CM/DIFF	39	0.256	0.061
500 Hz CM/DIFF	40	0.419	<i>0.004</i>
750 Hz CM/DIFF	37	0.270	0.055
1000 Hz CM/DIFF	34	0.391	<i>0.011</i>
250 Hz ANN/SUM	39	0.095	0.285
500 Hz ANN/SUM	39	0.280	<i>0.042</i>
750 Hz ANN/SUM	37	0.185	0.140
1000 Hz ANN/SUM	35	0.111	<i>0.035</i>